has brought up the important question of whether reduced-toxicity conditioning regimens improve the results of hematopoietic stem-cell transplantation (HSCT) in metabolic diseases. Reduced-intensity conditioning is increasingly used for HSCT, especially in elderly patients or those with medical problems, who cannot tolerate full myeloablative conditioning. 2, 3 We agree that less toxic regimens are also of interest for HSCT in children. 4 However, we question whether reduced-intensity is the optimal form of conditioning for HSCT in all patients with non-malignant disorders. For patients with severe immunodeficiencies, full myeloablative conditioning may represent overtreatment. Indeed, the group from Great Ormond Street showed encouraging results, using reducedintensity conditioning consisting of fludarabine combined with melphalan for patients with severe combined immunodeficiencies. 5 In 13 children with non-malignant disorders, Jacobsohn et al.
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1 has brought up the important question of whether reduced-toxicity conditioning regimens improve the results of hematopoietic stem-cell transplantation (HSCT) in metabolic diseases. Reduced-intensity conditioning is increasingly used for HSCT, especially in elderly patients or those with medical problems, who cannot tolerate full myeloablative conditioning. 2, 3 We agree that less toxic regimens are also of interest for HSCT in children. 4 However, we question whether reduced-intensity is the optimal form of conditioning for HSCT in all patients with non-malignant disorders. For patients with severe immunodeficiencies, full myeloablative conditioning may represent overtreatment. Indeed, the group from Great Ormond Street showed encouraging results, using reducedintensity conditioning consisting of fludarabine combined with melphalan for patients with severe combined immunodeficiencies. 5 In 13 children with non-malignant disorders, Jacobsohn et al. 6 used reduced-intensity conditioning and grafts from related and unrelated donors and reported an overall transplant-related mortality of 31% and a 3-year survival of 60%. In our experience from 1993, using HLA-A, -B and -DRb1 unrelated identical or related donors for HSCT for non-malignant disorders, including severe aplastic anemia, who failed immunosuppressive therapy (n ¼ 23) and inborn errors of metabolism (n ¼ 33), 5-year survival rates were 87% with HLAidentical sibling donors and 70% with unrelated donors, respectively ( Figure 1 ). We studied 43 children and 13 adults with a median age of 7 (range 0-56) years. All patients received full myeloablative conditioning consisting of cyclophosphamide and total body irradiation or busulfan. 7 Although attractive, because of low early toxicity, reduced-conditioning HSCT may be associated with more problems in the long term. First, there may be an increased risk of graft failure. This may be especially pronounced in non-malignant diseases. Patients with hemoglobinopathies may be immunized by several previous blood transfusions. Indeed, Jacobsohn et al. 6 also reported that only one of four patients with hemoglobinopathies had stable longterm engraftment. Furthermore, the use of peripheral blood stem cells may be unsuitable in non-malignant diseases because of the increased risk of extensive chronic graftversus-host-disease (GVHD), compared to bone marrow as source of stem cells. 8 Thus, 3/8 evaluable patients in the report by Jacobsohn et al. 6 developed extensive chronic GVHD, of whom one died. In our experience of using bone marrow and myeloablative conditioning, none of 38 children observed more than 3 months with non-malignant disorders developed extensive chronic GVHD.
It has been argued that patients treated with reducedintensity conditioning can be treated as outpatients. Isolation after HSCT may not be necessary, regardless of what conditioning is used. We showed that home care is safe for adult patients undergoing myeloablative conditioning for HSCT and results in lower transplantation-related mortality rates and better survival rates, compared with patients kept in isolation rooms in hospital. 9 It is not known whether a reduced-intensity conditioning will improve the outcome in HSCT or not. Accordingly, there is now a need for prospective randomized studies comparing reduced intensity with myeloablative conditioning for HSCT. We have an ongoing randomized study comparing the two regimens in patients undergoing HSCT for chronic myeloid leukemia and acute myeloid leukemia. Patient accrual has been difficult, because elderly and disabled patients are selected for reduced-intensity conditioning and patients with a high risk of relapse are selected for myeloablative conditioning, leaving few patients for the trial.
In the selection of therapy for non-malignant disorders, those who have received several blood transfusions, having a risk for immunization, are more likely to be selected for full myeloablative conditioning. Those who are immunocompromised will be selected for reduced-intensity con- ditioning. However, in the vast majority of patients with inborn errors of metabolism who have not received previous chemotherapy and have an intact immune system, an effective immunosuppressive conditioning is needed to prevent rejection. Furthermore, these disorders are rare, and therefore multicenter trials are necessary to obtain the statistical power needed for comparative studies. Until then, we will need to rely on accumulated pilot studies. In the future, when there is more experience, retrospective studies may provide information on which patients with non-malignant diseases can receive reduced-intensity conditioning instead of myeloablative conditioning. 
